Basel, 01 February 2019 CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people with severe haemophilia A without... Read more
Basel, 30 January 2019 Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) – other company programmes in AD continue The Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continues Roche remains committed to ongoing clinical studies in Alzheimer’s disease, including GRADUATE Phase... Read more
Basel, 17 January 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for... Read more
DISTRIBUTION AGREEMENT ANNOUNCEMENT January 14, 2019 Merck and Roche Renew Global Distribution Agreement Global distribution agreement renewed under existing terms for additional five years Includes Biochemical Reagents and Kapa Biosystems portfolios, and select qPCR & Nucleic Acid Purification products Merck and Roche have agreed to renew their current distribution agreement for the Biochemical Reagents and... Read more
cobas pro integrated solutions enhances automated procedures to overcome key challenges in lab management This new Serum Work Area solution in the cobas family minimizes hands-on time and maximizes productivity through automated procedures This new innovation offers flexibility for future changing testing needs, enabling labs to further deliver quality patient care Basel, 9 Jan. 2019 Roche (SIX: RO,... Read more
Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more
Basel, 10 December 2018 New member proposed for election to Roche Board of Directors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. The BoD... Read more
Basel, 10 December 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Daniel O’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. Until the end of February 2019 and prior to assuming new... Read more
Basel, 07 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no... Read more
Basel, 05 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared... Read more